INTRODUCTION

METHODS
Subjects
Thirty consecutive BD patients with ocular involvement but without explicit neurological involvement in the nonactive phase of their illness were applied neurological examination at the Neurology Department of Bakirkoy Training and Research Hospital for Psychiatry, Neurology and Neurosurgery. None of our patients had long term treatment and systemic conditions such as hypertension, diabetes, thyroid disorder or avitaminosis. The subjects' physical examination and blood test results were within normal limits. Patients with severe ocular involvement were excluded because of blindness might interfere with the neuropsychological tests. Twenty demographically matched healthy subjects, either volunteers or relatives, were used as controls. They performed a comprehensive battery of neuropsychological tests, and answered the anxiety and depression scales. Hospital's ethics committee approved the study and all subjects gave their informed consent.
Neurological Examination
Patients and controls were interviewed and undergone neurological examination about headache, motor symptoms, brainstem findings, disarthria, behavioral changes, dementia, seizure, cerebellar symptoms, sensory symptoms, movement disorders, hearing loss, and sphincter dysfunction. Patients with a history of perinatal brain injury, previous head trauma or any other disease that could have caused abnormal findings on neurological examination were excluded. Headache classification was performed in accordance with the International Classification of Headache Disorders 3rd edition (Beta version). None of the BD patients reported psychotic or mood disorder and all patients were sent for a cranial magnetic resonance imagining (MRI) with axial T1, T2, and proton weighted sequences.
Neuropsychological and Behavioral Evaluation
Subjects were evaluated by an experienced neuropsychologist who was unaware of patients' clinical diagnosis. Approximately 120 minutes were needed to perform the test battery. The validity and reliability of the Turkish versions of all tests were performed and reported previously. To evaluate the verbal and spatial memory, visuospatial skills, executive functioning and attention, following neuropsychological tests were applied on all patients and controls: 
11-Wechsler Adult Intelligence Scale (WAIS) Similarities and Comprehension Subtests
After neuropsychological tests, the Hamilton Anxiety Scale (HAM-A) and Beck Depression Inventory (BDI) were applied to all subjects to evaluate levels of depression and anxiety.
Ocular Examination
Ocular manifestations of BD were noted that monocular or binocular panuveitis, and retinal vasculitis.
Statistical Analysis
Chi-square test, the t-test, Pearson's and Spearman's rank correlation were performed for comparison of selected variables between groups. Neuropsychological performance was analysed by direct comparison of the raw test scores between the two groups. Significance was assumed at p<0.05. All statistical analyses were performed using SPSS Statistics 18.0. 
RESULTS
Demographic, Clinical, and Imaging Characteristics
Behavioral and Neuropsychological Evaluation
DISCUSSION
It has been shown that there are changes in cognitive functioning in BD patients with neurological involvement (9, 13, 14) . Brain abnormalities shown by neuroimagining techniques may explain this cognitive impairment. Studies of neuropsychological data in patients with BD without neurological manifestations are limited (15, 16) . In studies evaluating the cognitive performance of BD patients, it is shown that memory represents the most affected cognitive domain, followed by visuospatial/frontal executive functioning, and attention deficits are rarely affected than other cognitive abnormalities. Our study is a controlled study to evaluate cognition and silent neurological deficits in BD with ocular involvement using brain MRI. In our study, we found that memory and frontal functioning tests represented the most affected cognitive domains, and we did not detect attention deficits in BD patients. Memory deficits were as long-term learning, long-term recall, and immediate memory. Verbal and visual long-term memory deficits were the second major cognitive impairment domains; recognition memory deficit was not evaluated. Also our patients with BD showed higher scores on depression scales. It is well documentated that patients with depression should be more carefully evaluated for cognitive impairment.
Some of our BD patients had subcortical white matter lesions similar to neuroradiological findings as neuro-Behçet's disease patients. These results may demonstrate that subcortical contribution to cognitive dysfunction. Because of neurological manifestation of Behçet's disease is an important reason for comorbidity, we believe that it needs to be treated as early as possible either it is silent or overt manifestation.
Ocular involvement occurs in 67 to 95% of BD patients, and is usually in the late of the disease (17) . Ocular clinical findings include iridocyclitis, hypopyon, mild to moderate vitreitis, retinal vasculitis and occlusion, optic disc hyperemia, and macular edema. Ocular manifestations may be associated with neurologic manifestations (12, 18) . But there is not evidence about a relationship between ocular involvement and cognitive functioning in BD patients. International consensus recommendation for diagnostic criteria of neuro-Behçet's Disease (NBD) is the presence of neurological symptoms not otherwise explained by any other known systemic or neurological disease or treatment and in whom objective abnormalities are detected either on neurological examination, and/or with neuroimaging studies and cerebrospinal fluid (19) . The prevalence of NBD in BD is approximately 5-13% in nonselected large series (20, 21) . Shimizu reported that BD patients with elevated cerebral spinal fluid protein and/ or cell count without overt neurological involvement might be potential NBD developers (22) . Our patients did not have neurological complaints but after detailed neurological examination and MRI, we detected silent neurological findings.
Headache is the most common neurological symptom among patients with BD. Types of headaches among patients with BD are listed as nonstructural headache of BD, headache due to central nervous system parenchymal involvement, headache due to cerebral venous sinus thrombosis, headache in association with ocular inflammation and coexiting primary headaches (i. e., migraine; tension type headache) (1). Non-structural headache of BD is not primary neurological involvement in BD and it is not specific for BD, it is suggested that it may occur by the immune-mediated disease activity in susceptible individuals (23) . The most common neurological manifestation of our BD patients with ocular involvement was headache, especially non-structural headache. Number of patients with headache was higher than controls' but it was not statistically significant. Furthermore, presence of headache was not considered as an evidence of neurological involvement in BD.
We evaluated neuropsychiological performance and silent neurological deficits in BD with ocular involvement and found 46% cognitive impairment among BD patients. A similar cognitive change was observed by others as well. In a neuropsychological study of patients with neuro-Behçet syndrome, Öktem and colleagues found that memory impairment was the major finding (8) . The most severely affected memory process was delayed recall in the verbal and or visual modalities. Also attention deficit and deficits of executive functions of frontal system were other cognitive dysfunctions. They stated that neuropsychological status deteriorated insidiously, regardless of the neurological attacks, and the presence of cognitive decline was not directly related to lesions on neuroimaging at early stages of the disease.
Monastero and colleagues reported the cognitive functioning in BD patients without neurological involvement (15) . They examined the relationship between cognitive impairment and clinical variables for cognitive impairment, and anxiety and depression levels. Similar to our results, they found that cognitive impairment was evident in 46.1% of BD patients, with memory representing the cognitive domain most affected, especially visuospatial long-term memory, followed by longterm learning, long-term recall, and verbal and visual short term memory. It is suggested that BD patients with an active disease or treated with steroid are at potential risk of having subclinical cognitive deficits. Dutra and colleagues evaluated cognitive function in BD patients with and without neurological manifestations and to analyze clinical variables associated with cognitive deficits (24) . They found that both BD and NBD patients had impaired language and executive function, whereas visual memory was impaired only in NBD patients. They claimed that cognitive impairment occurs frequently in patients with BD independently of neurological manifestation and anxiety is a risk factor for cognitive impairment in BD. On behavioral evaluation of our patients, they showed higher scores on depression scales but anxiety scores were not statistically significant. Depression in our patients might be a risk factor for cognitive impairment. Severity of depression and depressive subtype have certain effects on neurocognitive task performance (25) .
It is difficult to comment on the clinical meaningfulness of relationship between cognitive impairment and depression in patients with BD. The neurocognitive declines and depression levels we assessed may be compared to those future studies of cognitive impairment in patients with BD. Siva and colleagues declared that patients with BD may develop a neurobehavioral syndrome, named "neuropsycho-Behçet syndrome" which consists of euphoria, disinhibition, psychomotor agitation or retardation, with paranoid attitudes and obsessive concerns (1) . They claimed that the development of psychiatric symptoms either at the onset of neurological symptoms of Neuro-Behçet's disease, or independently and these symptoms are not associated with glucocorticosteroid or any other therapy (26) . Only one of our patient had behavioral change as agitation. Our results support that BD patients with ocular involvement may be presented with psychiatric findings.
Gökçay et al. investigated the relationship between neuropsychological tests and P300 latancy values in patient groups with and without neurological involvement (14) . Unlike our and other studies, they showed that the patient group without neurological manifestations had normal neuropsychological test results whereas the one with neurological symptoms had abnormal results. The attention deficit was the most common abnormality. Our patients did not have attention deficits. Memory disturbance, in both verbal and visual modalities was the second most common cognitive dysfunction in their study. They found that P300 latencies of the neurologically impaired group were significantly longer than the controls and asymptomatic group. They suggested that these techniques could be applied to all BD patients to follow-up of the disease. These apparent differences may be due to methodology of their research.
As patients often develop neurological involvement after some nonneurological manifestations of BD, which greatly favours a correct diagnosis and early treatment (27) , Serdaroglu stressed "a careful neurological examination, including an extensive neuropsychological test battery, should be employed to detect this group" (28) . The results of our study suggest that there may be neuropsychological deficits, involving mainly memory, and executive functioning, subcortical MRI lesions and non-structural headache in BD patients with ocular involvement overt neurological manifestations. Our data strongly suggests the use of a standardised cognitive examination along with a detailed neurological evaluation in detecting subclinical neurological involvement in BD.
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